P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.

• Prithviraj Bose,
• Lucia Masarova,
• Naveen Pemmaraju,
• Mackenzie Dobbins,
• Nitin Jain,
• Hussein Abbas,
• Steven Kornblau,
• Abhishek Maiti,
• Ivo Veletic,
• Taghi Manshouri,
• Sharon Bledsoe,
• Mary Ann Richie,
• Nakiuda Hall-Moore,
• Lingsha Zhou,
• Xuemei Wang,
• Hagop Kantarjian,
• Zeev Estrov,
• Srdan Verstovsek

Affiliations

Prithviraj Bose

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Lucia Masarova

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Naveen Pemmaraju

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Mackenzie Dobbins

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Nitin Jain

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Hussein Abbas

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Steven Kornblau

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Abhishek Maiti

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Ivo Veletic

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Taghi Manshouri

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Sharon Bledsoe

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Mary Ann Richie

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Nakiuda Hall-Moore

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Lingsha Zhou

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Xuemei Wang

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Hagop Kantarjian

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Zeev Estrov

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Srdan Verstovsek

1 University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States